Stephen Bright

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Sanjay Ramakrishnan, Dan V. Nicolau, Beverly Langford et al. · The Lancet Respiratory Medicine · 2021 · 427 citations · Full text

Early Covid-19, Respiratory Diseases, Respiratory Infection +6

Kronic hysteria: Exploring the intersection between Australian synthetic cannabis legislation, the media, and drug-related harm

Stephen Bright, Brian Bishop, Robert Kane et al. · International Journal of Drug Policy · 2013 · 95 citations · Full text

Cannabis Use, Kronic Hysteria, Substance Abuse +15

Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial

Sanjay Ramakrishnan, Helen Jeffers, B Langford-Wiley et al. · The Lancet Respiratory Medicine · 2023 · 64 citations · Full text

Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold‐ hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA

Samuel D. Banister, Axel Adams, Richard C. Kevin et al. · Drug Testing and Analysis · 2018 · 57 citations · Full text

What can we say about substance use? Dominant discourses and narratives emergent from Australian media

Stephen Bright, Ali Marsh, Leigh M. Smith et al. · Addiction Research & Theory · 2008 · 39 citations · Full text

Substance Use, Pragmatic Analysis, Narrative And Identity +23